Pharnext Inks $3.5M

Pharnext SAS, a biopharma company developing treatments for neurological diseases, has closed on 2.5 million euro ($3.49 million) at a pre-money valuation of 60 million euro ($83.9 million), the company announced Thursday. Parinvest, La Financiere Gaspard and Truffle Capital invested in the round. The French company hopes to close on a total of 10 million euro by the end of the year.

North AmericaUSBriefs